1:19 PM
Jun 09, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA panel to discuss Avastin biosimilar from Amgen, Allergan

FDA’s Oncologic Drugs Advisory Committee (ODAC) will meet on July 13 to discuss a BLA for biosimilar ABP 215. Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) share rights to ABP 215,...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >